FY26 results: flat revenue, PAT drops about 30 percent YoY

EBITDA margin compressionResults View source PDF Explain this filing

GENCON · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.4%Reaction day

₹43.00

prior close

₹43.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.3%+2.7% vs market

Residential Commercial Projects peers, median of 65sector-1.0%+3.5% vs sector

On the reaction day the stock moved 2.7 pts more than Nifty Microcap 250 and 3.5 pts more than its Residential Commercial Projects peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.4

10m

-0.7

15m

-1.2

30m

+1.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.4-0.3+2.7-1.0+3.5

Next day

+2.3+0.8+1.5+0.0+2.3

-0.8+0.9-1.8+0.6-1.4

+0.7+1.8-1.1+0.5+0.2

+2.3+1.5+0.9+1.7+0.6

+0.9+1.7-0.8+1.6-0.7

-3.9-1.1-2.8-0.7-3.2

15d

-5.3+1.0-6.3+0.0-5.3

-7.7+0.4-8.1-0.4-7.3

+9.7+6.4+3.3+0.2+9.5

-15.1+5.5-20.6-3.8-11.3

UpDownMarket · Nifty Microcap 250Sector · Residential Commercial Projects peers, median of 65Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

FY26 consolidated revenue rose marginally to Rs 30,536.53 lakh from Rs 30,202.04 lakh YoY. However, PAT fell about 30 percent to Rs 850.46 lakh from Rs 1,213.39 lakh, hit by higher operating costs and lower other income. Q4 PAT dropped sharply to Rs 189 lakh vs Rs 620 lakh. EBITDA margin compressed. Auditor issued unmodified opinion. EPS at Rs 1.50 vs Rs 1.63. Operating cash flow improved to Rs 2,361 lakh.

Likely market impact

Weak profitability despite stable revenue; margin compression and sharp Q4 PAT decline may weigh on the stock.